MX377186B - Inhibidores de gelatinasa y uso de los mismos. - Google Patents
Inhibidores de gelatinasa y uso de los mismos.Info
- Publication number
- MX377186B MX377186B MX2018005259A MX2018005259A MX377186B MX 377186 B MX377186 B MX 377186B MX 2018005259 A MX2018005259 A MX 2018005259A MX 2018005259 A MX2018005259 A MX 2018005259A MX 377186 B MX377186 B MX 377186B
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- disease
- gelatinase inhibitors
- inflammatory
- gelatinases
- Prior art date
Links
- 239000002406 gelatinase inhibitor Substances 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000001914 Fragile X syndrome Diseases 0.000 abstract 1
- 102000013382 Gelatinases Human genes 0.000 abstract 1
- 108010026132 Gelatinases Proteins 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000032382 Ischaemic stroke Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000036626 Mental retardation Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 206010051739 Pulmonary sepsis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a nuevos inhibidores de gelatinasa, procedimientos para su preparación, composiciones farmacéuticas que los comprenden, y su uso en la terapia y/o profilaxis de afecciones en las que la inhibición de ñas gelatinasas es útil tal como epilepsia, esquizofrenia, enfermedad de Alzheimer, autismo (en particular, asociado al síndrome del cromosoma X frágil), retraso mental, trastornos del estado de ánimo tales como trastornos bipolares, depresión, vasculopatias tales como apoplejía isquémica y aterosclerosis, enfermedades inflamatorias tales como esclerosis múltiple, artritis reumatoide y enfermedad inflamatoria del intestino, toxicomanía, dolor neurópatico, enfermedades pulmonares tales como asma y enfermedad pulmonar obstructiva crónica, cáncer y septicemia. Adicción a las drogas, dolor neuropático, enfermedades pulmonares como asma y enfermedad pulmonar obstructiva crónica, cáncer y sepsis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382567 | 2015-11-16 | ||
| PCT/EP2016/077632 WO2017085034A1 (en) | 2015-11-16 | 2016-11-15 | Gelatinase inhibitors and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018005259A MX2018005259A (es) | 2018-08-16 |
| MX377186B true MX377186B (es) | 2025-03-07 |
Family
ID=54754574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018005259A MX377186B (es) | 2015-11-16 | 2016-11-15 | Inhibidores de gelatinasa y uso de los mismos. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10414797B2 (es) |
| EP (1) | EP3377515B1 (es) |
| JP (1) | JP6795606B2 (es) |
| KR (1) | KR102649684B1 (es) |
| CN (1) | CN108290925B (es) |
| AU (1) | AU2016356876B2 (es) |
| BR (1) | BR112018009641A2 (es) |
| CA (1) | CA3002892A1 (es) |
| EA (1) | EA036732B1 (es) |
| ES (1) | ES2766548T3 (es) |
| IL (1) | IL259286B (es) |
| MX (1) | MX377186B (es) |
| WO (1) | WO2017085034A1 (es) |
| ZA (1) | ZA201803212B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107987126B (zh) * | 2017-12-18 | 2018-10-02 | 哈尔滨工业大学 | 4位苯丙酰胺羟基化修饰的内吗啡肽类似物及其合成方法和应用 |
| KR20230097018A (ko) * | 2020-11-05 | 2023-06-30 | 추가이 세이야쿠 가부시키가이샤 | 다이케토피페라진 형성에 의한 결손을 억제하는 펩타이드 합성 방법 |
| EP4714940A1 (en) | 2024-09-23 | 2026-03-25 | Accure Therapeutics, S.L. | Gelatinase inhibitors and use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2573006B2 (ja) * | 1987-12-17 | 1997-01-16 | 富士薬品工業株式会社 | 新規なヒドロキサム酸誘導体 |
| WO1992022523A2 (en) * | 1991-06-14 | 1992-12-23 | Research Corporation Technologies, Inc. | Peptide derivatives of collagenase inhibitor |
| WO1998015525A1 (en) | 1996-10-07 | 1998-04-16 | Sumitomo Pharmaceuticals Co., Ltd. | Hydroxamic acids |
| WO2009097893A1 (en) * | 2008-02-04 | 2009-08-13 | Proyecto De Biomedicina Cima, S.L. | Methods for the treatment of cardiac disease associated to myocardial fibrosis using an inhibitor of pcp |
-
2016
- 2016-11-15 MX MX2018005259A patent/MX377186B/es active IP Right Grant
- 2016-11-15 US US15/776,296 patent/US10414797B2/en active Active
- 2016-11-15 CN CN201680066867.4A patent/CN108290925B/zh active Active
- 2016-11-15 JP JP2018544414A patent/JP6795606B2/ja active Active
- 2016-11-15 ES ES16795077T patent/ES2766548T3/es active Active
- 2016-11-15 WO PCT/EP2016/077632 patent/WO2017085034A1/en not_active Ceased
- 2016-11-15 EA EA201891184A patent/EA036732B1/ru unknown
- 2016-11-15 AU AU2016356876A patent/AU2016356876B2/en active Active
- 2016-11-15 CA CA3002892A patent/CA3002892A1/en active Pending
- 2016-11-15 KR KR1020187016673A patent/KR102649684B1/ko active Active
- 2016-11-15 BR BR112018009641-5A patent/BR112018009641A2/pt not_active Application Discontinuation
- 2016-11-15 EP EP16795077.3A patent/EP3377515B1/en active Active
-
2018
- 2018-05-10 IL IL259286A patent/IL259286B/en unknown
- 2018-05-15 ZA ZA2018/03212A patent/ZA201803212B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3002892A1 (en) | 2017-05-26 |
| AU2016356876B2 (en) | 2020-10-01 |
| US20180319839A1 (en) | 2018-11-08 |
| MX2018005259A (es) | 2018-08-16 |
| BR112018009641A2 (pt) | 2018-11-06 |
| KR20180071388A (ko) | 2018-06-27 |
| JP6795606B2 (ja) | 2020-12-02 |
| EA201891184A1 (ru) | 2018-11-30 |
| NZ741898A (en) | 2024-02-23 |
| EA036732B1 (ru) | 2020-12-14 |
| ES2766548T3 (es) | 2020-06-12 |
| US10414797B2 (en) | 2019-09-17 |
| KR102649684B1 (ko) | 2024-03-21 |
| JP2018535258A (ja) | 2018-11-29 |
| IL259286A (en) | 2018-07-31 |
| HK1255029A1 (en) | 2019-08-02 |
| CN108290925A (zh) | 2018-07-17 |
| CN108290925B (zh) | 2021-12-24 |
| EP3377515B1 (en) | 2019-10-30 |
| IL259286B (en) | 2021-10-31 |
| WO2017085034A1 (en) | 2017-05-26 |
| ZA201803212B (en) | 2020-08-26 |
| AU2016356876A1 (en) | 2018-05-10 |
| EP3377515A1 (en) | 2018-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ741082A (en) | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses | |
| MX2021015106A (es) | Inhibidores de ferroportina novedosos. | |
| UA117218C2 (uk) | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f | |
| MX375674B (es) | Compuestos de carboxamida inhibidores de la actividad de cinasa rip2. | |
| ZA201802496B (en) | Jak kinase inhibitor compounds for treatment of respiratory disease | |
| PH12014501029A1 (en) | Pharmaceutical compositions comprising glitazones and nrf2 activators | |
| MX2018002631A (es) | Inhibidores de molecula pequeña de dyrkia y usos de los mismos. | |
| EP3349762A4 (en) | CO CRYSTALS OF SGLT2 INHIBITORS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREFOR | |
| JOP20190001A1 (ar) | عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه | |
| IN2014DN07885A (es) | ||
| MX377186B (es) | Inhibidores de gelatinasa y uso de los mismos. | |
| BR112015018071A2 (pt) | estra-1,3,5(10),16-tetraeno-3-carboxamidas | |
| MX2019006863A (es) | Inhibidores de heparanasa y uso de los mismos. | |
| SA520412289B1 (ar) | مركبات مثبط الهدف الميكانيكي للراباميسين | |
| PH12017500383B1 (en) | Pyrazolothiazole compound and medicine comprising same | |
| WO2014108337A8 (en) | Pyrazolyl-based carboxamides i as crac channel inhibitors | |
| MX385381B (es) | Cristal de compuesto que tiene actividad inhibidora de la cinasa de janus (jak). | |
| EA201790321A1 (ru) | Эластомерные композиции, содержащие усниновую кислоту, и изделия, изготовленные из них или покрытые ими | |
| MX2020012065A (es) | Compuestos de ciclopentano. | |
| WO2014108336A8 (en) | Pyrazolyl-based carboxamides ii as crac channel inhibitors | |
| MX2020011472A (es) | Metodo de tratamiento y composiciones que comprenden un inhibidor de cinasa pi3k delta-gamma doble y un corticosteroide. | |
| PH12013501665A1 (en) | Cathepsin c inhibitors | |
| ZA202201221B (en) | Cyclopentane compounds | |
| UA113887C2 (xx) | 5-амінотетрагідрохінолін-2-карбонові кислоти і їх застосування | |
| UA113645C2 (xx) | ТРИАЗОЛОНИ ЯК ІНГІБІТОРИ mPGES-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| PD | Change of proprietorship |
Owner name: ACCURE THERAPEUTICS, S.L. |